Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Mar 31, 20 | -0.39
Increased by
+26.42%
|
-0.14
Decreased by
-178.57%
|
Nov 4, 19 | -0.14
Decreased by
-55.56%
|
-0.12
Decreased by
-16.67%
|
Aug 29, 19 | -0.25
Increased by
+75.00%
|
-0.13
Decreased by
-92.31%
|
May 29, 19 | -0.15
Increased by
+85.00%
|
-0.05
Decreased by
-200.00%
|
Sep 27, 18 | -0.53
Decreased by
-5.92 K%
|
-0.44
Decreased by
-20.45%
|
Aug 16, 18 | -0.09
Increased by
+91.00%
|
-0.47
Increased by
+80.85%
|
Mar 21, 18 | -1.00
Increased by
0.00%
|
-0.66
Decreased by
-51.52%
|
Nov 13, 17 | -1.00
Decreased by
-277.68 K%
|
-0.65
Decreased by
-53.85%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-5.68 M
Decreased by
-30.68%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-5.18 M
Increased by
+11.34%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-5.79 M
Increased by
+15.15%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-1.45 M
Decreased by
-200.65%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-4.35 M
Increased by
+47.74%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-5.84 M
Decreased by
-72.48%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-6.82 M
Increased by
+13.41%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 20 | 0.00
Decreased by
N/A%
|
1.44 M
Increased by
+156.21%
|
Increased by
+N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.